1. STINGa enhances mAb immunotherapy in BCL1 lymphoma in an FcγR-dependent manner.
STINGa enhances mAb immunotherapy in BCL1 lymphoma in an FcγR-dependent manner. A, Experimental plan to assess the effect of DMXAA on mAb immunotherapy. B and C, FcγR expression (B) and A:I ratio (C) on splenic macrophages on day 21 after BCL1 inoculation (error bar ± SEM). D–F, Kaplan–Meier survival curve for WT BALB/c mice (D), FcγR-null BALB/c (E), or WT BALB/c (F) in the presence or absence of CD8+ T-cell–depleting antibody (n = 8–10, Mantel–Cox test).
Lekh N. Dahal et al. Cancer Res 2017;77:
©2017 by American Association for Cancer Research